Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Stocks in this Quantisnow insightHealth Care
Historical context for MDCX
Across the 26 sessions after earlier MDCX headlines, the stock closed higher 9 times and lower 16 times, with a median move of 5.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MDCX | SPY |
|---|---|---|---|
| May 6, 2026 | Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response | +20.9% | +1.4% |
| Apr 27, 2026 | Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill | -5.7% | +0.2% |
| Apr 17, 2026 | Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome | +17.0% | +1.2% |
| Apr 15, 2026 | Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression | -25.1% | +0.8% |
| Apr 6, 2026 | Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention | +9.8% | +0.5% |
| Apr 1, 2026 | Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset | -8.5% | +0.8% |
Keep researching MDCX
Quantisnow market dataNASDAQ
MDCX
Medicus Pharma Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for MDCX
Full MDCX profile on Quantisnow Follow MDCX and get a push notification the moment its next story breaks.